• About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • #5613 (no title)
Menu
  • About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • #5613 (no title)
Contact Us
  • About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • Contact Us
Menu
  • About Us
  • Why MenaQ7®️
  • K2 Science
  • News & Events
    • News & Press
    • Event Calendar
  • Partners
  • Contact Us
Contact Us

Featured story

K2 is the Micro-calcification Bullet: New Paper

Vitamin K2 featured in new CV calcification paper, supported by NattoPharma, published in Euro Journal of Preventive Cardiology.

The European Journal of Preventive Cardiology has published a new review paper examining the link between micro-calcification and atherosclerosis, focusing on cardiovascular imaging techniques and evaluating the concept of vitamin K supplementation to preserve cardiovascular health. The review paper, the result of the INTRICARE grant awarded to NattoPharma’s International Research Network by the European Union within the Horizon 2020 Marie Skłodowska-Curie research and innovation program, is another strong piece of evidence identifying vitamin K2 as an essential cardiovascular nutrient.

The authors of “Locking and loading the bullet against micro-calcification”[1], identified the most suitable technique for detecting micro-calcification and assessed state-of-the-art meta-analysis and clinical studies to identify possible treatment options and evaluate the concept of vitamin K supplementation to preserve vascular health. “Despite recent medical advances, cardiovascular disease remains the leading cause of death worldwide,” says Prof. Schurgers, Professor of Biochemistry of Vascular Calcification and Vice Chair of Biochemistry at the Cardiovascular Research Institute Maastricht (CARIM), Maastricht University. “Our exhaustive, structured PubMed search showed that 18F-socium fluoride (18F-NaF) PET is the most suitable technique for detecting active micro-calcification, a hallmark of atherosclerosis.”

Presenting the pros and cons of available treatments, “vitamin K supplementation should be considered as a possible safe and cost-effective option to inhibit vascular (micro)-calcification,” the paper concludes.

The paper is significant because it adds to the growing body of evidence substantiating vitamin K2 as an essential cardiovascular support nutrient, according to NattoPharma Chief Medical Officer Dr. Hogne Vik.

“There are some who view atherosclerosis as an age-related condition – that calcification simply builds up over time. NattoPharma contends that this condition is not simply age-related; rather, that atherosclerosis is the product of a vitamin deficiency: vitamin K2,” says Dr. Vik. “Matrix Gla Protein (MGP) is the most potent known inhibitor of vascular calcification to date. MGP is a K-dependent protein already present in the body, but it needs adequate Vitamin K2 in order to be activated to perform its function. Our three-year clinical study[2] of healthy postmenopausal women showed that 180mcg of MenaQ7 Vitamin K2 as MK-7 daily resulted in not only cessation, but remarkably regression in arterial stiffness (i.e., their arteries became more flexible) in the MenaQ7 group through activation of MGP.”

It is important to note that no other compound to date has been able to produce the results experienced with a daily nutritional dose of Vitamin K2 as MK-7 (as MenaQ7®),” Dr. Vik adds. “This study has served as a platform for other clinical trials investigating K2 in patient populations with existing coronary artery calcification, aortic valve calcification, and peripheral artery calcification, and these studies are being driven by the medical community.”

“The work conducted in collaboration with NattoPharma under the INTRICARE grant has not only helped us shine a light on the most reliable technique for detecting active micro-calcification, providing some hope in getting ahead of compromised cardiovascular health, but also the science supporting various therapy options, including supplementation,” says Prof. Schurgers. “Essentially, this work will help drive awareness how we can ‘lock in’ on the effects of vascular calcification (18F-NaF PET) and ‘load’ a suitable, cost-effective bullet (vitamin K).”

The review paper is the result of the INTRICARE (grant agreement No 722609) grant funded by the European Union within the Horizon 2020 Marie Skłodowska-Curie research and innovation program, awarded to NattoPharma’s International Research Network to train a total of 26 Early Stage Researchers (ESRs) focusing on harnessing endogenous mechanisms for health and the effect of vitamin K to hold or regress microcalcification and subsequent cardiovascular disease.

References:
1 Florea A, Morgenroth A, Bucerius J, Schurgers LJ, Mottaghy FM. Locking and loading the bullet against micro-calcification. Euro J Prev Cardiology (2020) 0(00) 1-8. doi:10.1177/2047487320911138
2 Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thromb Haemost. 2015 May;113(5):1135-44. Doi: 10.1160/TH14-08-0675.
PR: NattoPharma Research Network Receives 4M€ Research Grant

Share on:
Share on facebook
Share on twitter
Share on linkedin

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor

NattoPharma
  • Mission & Purpose
  • K2 Timeline
  • Management Team
  • K2 Science
  • K2 in Numbers
  • Mission & Purpose
  • K2 Timeline
  • Management Team
  • K2 Science
  • K2 in Numbers
MenaQ7®️
  • Why MenaQ7®️
  • Quality Statement
  • Benefits
  • Partner Benefits
News & Events
  • News & Press
  • Event Calendar
Contact Us

Let's improve health!

How can we help?
  • Oslo, Norway (Main)
  • New Jersey, USA
  • Contact Us
© Copyright 2022 NattoPharma.
All rights reserved

We value your privacy

We access information on a device, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for personalised ads and content, ad and content measurement, and audience insights, as well as to develop and improve products.

With your permission we and our partners may use precise geolocation data and identification through device scanning. You may click to consent to our and our partners’ processing as described above. Alternatively you may click to refuse to consent or access more detailed information and change your preferences before consenting.

Please note that some processing of your personal data may not require your consent, but you have a right to object to such processing. Your preferences will apply to this website only. You can change your preferences at any time by returning to this site or visit our privacy policy.

Agree
Disagree